1. A method of treating psoriasis in a subject, comprising administering to the subject an antibody or antigen binding portion thereof that is capable of binding to an epitope of the p40 subunit of IL-12 and / or IL-23, wherein the subject has at least a PASI 75 response for the first long period after initial administration of the antibody or its antigen binding part, where the subject has a decrease in response after cessation of administration of the antibody or its antigen binding part, and where the subject has at least a PASI 75 response for a second long period after repeated administration of the antibody or its antigen binding part, thereby treating psoriasis in a subject. 2. The method of claim 1, wherein the first long period is at least about 12 weeks. The method of claim 1, wherein administration of the antibody is stopped for at least about 12 weeks. The method of claim 1, wherein the second long period is at least about 12 weeks. The method of claim 1, wherein the antibody or antigen binding portion thereof is administered once every two weeks. The method of claim 1, wherein the antibody or antigen binding portion thereof is administered once a week. The method of claim 1, wherein the antibody or antigen binding portion thereof is administered in a single dose. The method of claim 1, wherein the antibody or antigen binding portion thereof is administered at a dose of about 200 mg. The method of claim 1, wherein the antibody or antigen binding portion thereof is administered at a dose of about 100 mg. The method of claim 1, wherein psoriasis is chronic psoriasis. A method for treating psoriasis in a subject, comprising administering to the subject a single dose of an antibody or antigen binding portion thereof that are capable of binding to the p4 subunit epitope1. Способ лечения псориаза у субъекта, включающий введение субъекту антитела или его антигенсвязующей части, которые способны связываться с эпитопом субъединицы p40 IL-12 и/или IL-23, где у суб
